IPO News | Mingyu Pharmaceutical submits to the main board of the Hong Kong Stock Exchange

Zhitongcaijing · 11/24/2025 13:09

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange disclosure on November 24, Mingyu Pharmaceutical Co., Ltd. (Mingyu Pharmaceuticals for short) submitted an order to the main board of the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities as co-sponsors. According to the prospectus, Mingyu Pharmaceutical was founded in 2018 and is an innovative biotechnology enterprise. The company has a dual growth engine: a robust clinical-stage tumor product portfolio based on a proprietary antibody-conjugated drug (ADC) platform and a novel PD-1/VEGF bispecific antibody (BsAB), and its own immune assets that are already in the advanced clinical stages of commercialization.

As of November 16, 2025, the company has 13 candidate products in its pipeline, 10 of which are in the clinical phase. The company's autoimmunity program is expected to generate revenue in the near future. The oncology project focuses on promoting ADC monotherapy for late-line treatment and exploring combination therapies with PD-1/VEGF bispecific antibodies to revolutionize first-line cancer treatment.

image.png